Seven Innovative Biopharma Companies Secure New Funding Rounds

According to public information, last week (June 9th ~ June 15th),Globally, there isAt least 7A New Pioneer Company Dedicated to Innovative Drug Development Announces Completion of a New Round of Financing. After梳理, the products being developed by these new companies favored by capital includeRadiopharmaceuticals, Peptides, Gene Therapy Drugs, Small Molecule Drugsetc., focusing on disease areas covering cancer, neurological disorders such as depression, obstructive sleep apnea (OSA), etc.

AB-RayBio

Financing Round: Angel Round

Financing Amount: Tens of Millions of Yuan

On June 13, AB-RayBio Therapeutics (referred to as "AB-RayBio"), completed an angel round of financing worth tens of millions of RMB. This round was led by Hangshi Asset Management, with participation from Zhengjing Capital and Binjiang 5050. The funds raised will primarily be used for preclinical and early clinical development of the company's existing pipeline. Founded in May 2024, AB-RayBio is an innovative drug company in the clinical research stage, focusing on...Novel Targeted RadiopharmaceuticalsThe development. The company focuses on overcoming major diseases such as cancer, aiming to provide an integrated solution for precise diagnosis and targeted treatment in clinical settings. AB-RayBio currently has 8 pipelines under research, among which the JJH002 pipeline has shown excellent data and is already in the IIT stage and preparing for IND application.

Enterome

Financing Round: Undisclosed

Financing Amount: 19 Million US Dollars

On June 12, Enterome announced that it had raised $19 million through a new round of private financing to advance its lead clinical program, EO2463 OncoMimics immunotherapy, for the treatment of indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and complete the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare for the registration trial of the candidate drug.EO2463 is an innovative ready-to-use immunotherapy candidate drug composed of four peptides mimicking B-cell tumor-associated antigens CD20, CD22, CD37, and CD268 (BAFF receptor), as well as the auxiliary UCP2 peptide, capable of activating anti-tumor immune responses and eliminating cancerous B cells.Enterome's OncoMimics pipeline includes three clinical-stage candidates: EO2463 for the treatment of indolent non-Hodgkin lymphoma; EO4010 for third-line colorectal cancer; and EO2401 for glioblastoma and adrenal tumors. These candidates have all demonstrated positive early clinical efficacy as well as safety and tolerability.

Innovecbio

Financing Round: A+ Round

Financing Amount: Tens of Millions of Yuan

On June 12, InnoVec Biotherapeutics Inc. (referred to as "Innovecbio"),InnoVec Biotherapeutics) announced the completion of a multi-million yuan A+ round of financing. This round of investment was led by Tiance Capital, with participation from new investors and existing shareholders. The funds raised will be mainly used for the clinical validation and advancement of the company’s product pipeline, as well as the innovation of its gene delivery platform. Innovecbio is a clinical-stage gene therapy company driven by vector innovation, dedicated to developing gene therapy delivery tools suitable for human application, enabling gene therapy to be widely applied to both rare and common diseases.Innovecbio focuses on multiple disease areas including ophthalmology, neurology, and musculature, with several innovative products already entering the IIT and IND stages.

Elkedonia

Funding Round: Seed Round

Financing Amount: 11.25 Million Euros

On June 11, Elkedonia announced the successful completion of a €11.25 million seed financing round. This round was co-led by Kurma Partners, WE Life Sciences, and the French Tech Seed Fund, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est, and Sambrinvest.Elkedonia Focuses on Novel Intracellular Target Elk1 — A Protein Playing a Key Role in Reward Circuitry and Neuroplasticity, Mechanisms That Go Awry in Diseases Such as Depression, Post-Traumatic Stress Disorder (PTSD), and Addiction.Elkedonia is developing a neuroplasticity drug aimed at restoring neuroplasticity without causing the side effects associated with hallucinogens or ketamine derivatives. Preclinical and clinical research evidence suggests that inhibiting Elk1 is an effective approach for the rapid treatment of depression, without common side effects such as sedation, dependency, and hallucinations found in current antidepressant therapies.

Antares Therapeutics

Financing Round: Series A

Financing Amount: 177 Million US Dollars

On June 10, Antares Therapeutics announced the launch of a $177 million Series A financing round. This round was co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors. Antares is a spin-off company of Scorpion Therapeutics, which in March 2025 licensed its mutation-selective PI3Kα inhibitor program, STX-478, to Eli Lilly and Company for up to $2.5 billion in total consideration. Over five years, Scorpion Therapeutics has raised a cumulative $420 million in financing, formed collaborations with multiple pharmaceutical companies, and generated six development candidates, three of which have entered clinical testing.Antares is advancing a pipeline of small molecule assets, including precision oncology and other therapeutic areas., the company also announced an agreement with Pierre Fabre, who obtained two clinical-stageHighly Selective Next-Generation Mutant EGFR Inhibitor(Global rights for the treatment of non-small cell lung cancer).

32 Biosciences

Financing Round: Undisclosed

Financing Amount: 6 Million US Dollars

On June 10, 32 Biosciences announced that it had secured $6 million in financing to support the ongoing development of its lead asset. The company’s therapeutic innovation is a non-antibiotic antibacterial agent that prevents intestinal bacterial infections by inhibiting virulence gene expression, enhancing the intestinal mucosal barrier, and promoting the growth of beneficial bacteria. This therapy is expected to significantly reduce infection rates and infection-related mortality without contributing to antibiotic resistance.

Mosanna Therapeutics

Financing Round: Series A

Financing Amount: 80 Million US Dollars

On June 9, clinical-stage biotechnology company Mosanna Therapeutics announced the completion of an $80 million Series A financing round.The company is developing a convenient nasal spray for nighttime use, aimed at treating obstructive sleep apnea (OSA) by restoring the body's natural airway regulation function.This round of financing was led by EQT Life Sciences and Pivotal bioVenture Partners, with Forbion, Broadview Ventures, and Norwest co-leading. Founding investor Forty51 Ventures, along with Supermoon Capital and High-Tech Gründerfonds (HTGF), also participated in the investment.The mechanism of action of MOS118 is to target the upper airway muscles that maintain airway patency, restoring the natural airway reflex function that is weakened in patients during the night.The press release introduced that the breakthrough of Mosanna lies in regarding sleep apnea as a neuromuscular dysfunction rather than a purely mechanical issue. MOS118 is expected to become the first therapy to restore the body's natural airway reflex through a nasal spray, which is likely to significantly improve patient compliance and treatment outcomes for those who have lacked effective treatment options over the long term.

References:

[1]Official websites of various companies and publicly available information